Results 1 to 10 of about 9,630 (208)
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]
Cochrane Database of Systematic Reviews, 2016 This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this ...
Duarte, GS +7 more
+9 more sources
Archives of Rehabilitation Research and Clinical Translation, 2021 Objectives: The objectives of this study were to evaluate whether botulinum toxin type A (BoNT-A) treatment for lower limb spasticity leads to patient goal attainment and identify factors associated with positive goal attainment and to assess the effect ...
Subbuh Choudhry, MBBS +4 more
doaj +1 more source
Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review
Toxins, 2021 Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis.
Emanuela Martina +4 more
doaj +1 more source
Toxins, 2021 Several studies have investigated the effect of botulinum toxin A (BoNT-A) for managing chronic musculoskeletal pain, bringing contrasting results to the forefront.
Simone Battista +7 more
doaj +1 more source
Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy [PDF]
Anais Brasileiros de Dermatologia, 2014 BACKGROUND: Masseter hypertrophy has been treated with botulinum toxin injections because of esthetic complaints especially in Asians. OBJECTIVES: The goal of the present study was to evaluate the efficacy of abobotulin toxin use in masseter hipertrophy ...
Fernanda Homem de Mello de Souza Klein +4 more
doaj +2 more sources
Botulinum Toxin Type A for Treatment of Masseter Hypertrophy: Volumetric Analysis of Masseter Muscle Reduction over Time [PDF]
Archives of Aesthetic Plastic Surgery, 2016 Background There has been increasing interest in facial contouring procedures throughout Asian countries. As such, botulinum toxin A injections for masseteric hypertrophy have become a common procedure provided to patients who desire non-surgical ...
Edward Ilho Lee +4 more
doaj +1 more source
ABCS Health Sciences, 2022 Introduction: The use of botulinum toxin type A (BTX-A) to correct gummy smile has become popular in recent years. Objective: To evaluate the effects of BTX-A application in the correction of gummy smile 2 and 32 weeks after application.
Carlos Eduardo Alonso Vieira +7 more
doaj +1 more source
Botulinum toxin type A therapy for blepharospasm [PDF]
Cochrane Database of Systematic Reviews, 2020 This is an update of a Cochrane Review first published in 2005. Blepharospasm is the second most common form of focal dystonia. It is a disabling disorder, characterised by chronic, intermittent or persistent, involuntary eyelid closure, due to spasmodic contractions of the orbicularis oculi muscles.
Duarte, GS +7 more
openaire +5 more sources
Toxins, 2021 Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common disabling consequence of many neurological diseases. Electrical stimulation of motor nerve endings has been reported to boost the effect of BoNT-A. To date, a wide
Alessandro Picelli +6 more
doaj +1 more source
rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
Frontiers in Microbiology, 2022 Botulinum neurotoxin (BoNT) is one of the most dangerous bacterial toxins and a potential biological weapon component. BoNT mechanism of pathological action is based on inhibiting the release of neurotransmitters from nerve endings.
Artem A. Derkaev +9 more
doaj +1 more source